A Choice for Balanced Birth Control
Balcoltra® balances high effectiveness with a low dose of hormones1
Not an actual patient.
Is Balcoltra Right For Me?
Take the quiz and bring the results to your doctor to discuss whether Balcoltra is a good option for you.
An Effective Way to Prevent Pregnancy
Balcoltra is a birth control pill that includes levonorgestrel, a widely studied hormone commonly used in oral contraceptives and intrauterine devices (IUDs).
Not actual patients.
Balcoltra is highly effective, with about 1 woman per 100 woman-years becoming unintentionally pregnant while using Balcoltra.1,2
*Most eligible patients will pay no more than $21 per co-pay. Present your coupon with your prescription to your participating pharmacy. For each Balcoltra prescription, pay the first $21 of your out-of-pocket expense and Avion will cover up to $100 of your remaining expense. You could have additional responsibility depending on your insurance plan or remaining expense. This offer is good for 21 uses. Cardholders with questions, please call 1-877-838-3846 (8:30 AM-5:30 PM ET, Monday-Friday).
What is Balcoltra?
Balcoltra is a prescription birth control pill used for the prevention of pregnancy.
IMPORTANT RISK INFORMATION for Balcoltra (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets)
WARNING TO WOMEN WHO SMOKE
Do not use Balcoltra if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots, or stroke. This risk increases with age and the number of cigarettes you smoke.
Who should not take Balcoltra?
Do not use Balcoltra if you have or have had blood clots, history of heart attack or stroke, high blood pressure that medicine cannot control, breast cancer or any cancer that is sensitive to female hormones, liver disease or liver tumors, unexplained bleeding from the vagina, hypersensitivity to any of the components, if you are or may be pregnant, or if you take Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, as this may increase levels of liver enzymes in the blood.
What else should I know about taking Balcoltra?
Treatment with Balcoltra should be stopped if you have a blood clot, and at least 4 weeks before and through 2 weeks after major surgery. You should not take Balcoltra any earlier than 4 weeks after having a baby. If you are breastfeeding, talk to your doctor before taking Balcoltra. If you experience yellowing of the skin or eyes due to problems with your liver, you should stop taking Balcoltra. If you are prediabetic or diabetic, your doctor should monitor you while using Balcoltra. Your doctor should evaluate you if you have any significant change in headaches or irregular menstrual bleeding. Balcoltra contains FD&C Yellow No. 5 and may cause an allergic reaction, including in those with an allergy to aspirin.
What are the most serious risks of taking Balcoltra?
Balcoltra increases the risk of serious conditions, including blood clots, stroke, and heart attack. These can be life-threatening and require immediate medical care.
What are the possible side effects of Balcoltra?
The most common side effects of Balcoltra are headache, spotting or bleeding between periods or no menstrual bleeding, nausea, breast tenderness or pain, stomach pain, pain during periods, depression, acne, and vaginal infections.
Birth control pills do not protect you against any sexually transmitted disease, including HIV, the virus that causes AIDS.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088.
References: 1. Balcoltra [package insert]. Alpharetta, GA: Avion Pharmaceuticals LLC; 2018. 2. ClinicalTrials.gov, US National Library of Medicine (NLM). Bethesda, MD: National Institutes of Health; 2018. https://clinicaltrials.gov/ct2/results?cond=&term=%22levonorgestrel%22+%2B+%22ethinyl+estradiol%22&cntry=&state=&city=&dist=.. Accessed February 23, 2018.